Table 1 Demographic profiles in patients with schizophrenia and controls.
Variable | Patients (N = 625) | Controls (N = 400) | Statistic | p |
|---|---|---|---|---|
Age (years) | 45.03 ± 10.19 | 44.73 ± 13.50 | 0.37 | 0.71 |
Gender (male) | 512 (81.9%) | 157 (39.3%) | 159.90 | <0.0001 |
Education (years) | 8.45 ± 3.65 | 9.73 ± 5.60 | 4.06 | <0.0001 |
BMI | 23.97 ± 4.45 | 25.16 ± 4.26 | 4.20 | <0.0001 |
Onset age | 26.60 ± 20.19 | − | − | − |
Illness duration (years) | 21.14 ± 9.90 | − | − | − |
Atypical antipsychotic (n) | 439 | − | − | − |
Typical antipsychotic (n) | 186 | − | − | − |
Daily dose (mg/day) (chlorpromazine equivalents) | 390.35 ± 295.35 | − | − | − |
Antipsychotic treatment duration (months) | 31.37 ± 46.64 | − | − | − |
PANSS score | − | − | − | |
Positive symptoms | 11.92 ± 6.26 | − | − | − |
Negative symptoms | 20.14 ± 8.69 | − | − | − |
General psychopathology | 25.15 ± 7.11 | − | − | − |
Total score | 57.20 ± 16.51 | − | − | − |
